8-11-14-eicosatrienoic-acid and Psoriasis

8-11-14-eicosatrienoic-acid has been researched along with Psoriasis* in 5 studies

Other Studies

5 other study(ies) available for 8-11-14-eicosatrienoic-acid and Psoriasis

ArticleYear
Hepoxilin B3 and its enzymatically formed derivative trioxilin B3 are incorporated into phospholipids in psoriatic lesions.
    The Journal of investigative dermatology, 2002, Volume: 118, Issue:1

    In previous studies we observed that normal human epidermis forms 12-oxo-eicosatetraenoic acid (12-oxo-ETE) and hepoxilin B3 (HxB3) as major eicosanoids, both being elevated in psoriasis. We also observed that normal epidermis, in a reaction probably catalyzed by 12-lipoxygenase, only synthesize one of the two possible 10-hydroxy epimers of HxB3. We have now extended these previous studies investigating further transformation of HxB3 into trioxilin B3 (TrXB3) and esterification of both into phospholipids. Phospholipids were extracted from normal epidermis and from psoriatic scales. A combination of high performance liquid chromatography and gas chromatography-mass spectrometry analysis demonstrated the occurrence of HxB3 and TrXB3 in the phospholipids of psoriatic lesions. Alkaline- and phospholipase-A2-mediated hydrolysis of the phospholipids yielded similar quantities of both HxB3 and TrXB3 indicating their preference for the sn-2 position of glycerophospholipids. The thin layer chromatography analysis of the phospholipid classes after incubation of epidermal cells with [14C]-labeled HxB3, TrXB3, 12-hydroxy-eicosatetraenoic acid (12-HETE), 12-oxo-ETE, or 15-HETE showed that 12-HETE was the most esterified (12-HETE >15-HETE > TrXB3 > 12-oxo-ETE > HxB3). HxB3 and TrXB3 were mainly esterified in phosphatidyl-choline and phosphatidyl-ethanolamine. HxB3 was also enzymatically converted into TrXB3 in vitro. HxB3 epoxide hydrolase-like activity was not observed when boiled tissue was incubated with [14C]-HxB3, this activity being located in the cytosol fraction (100,000 x g supernatant) of fresh tissue. These findings suggest that in vivo some part of HxB3 is transformed into TrXB3 and both compounds are partially incorporated into the phospholipids.

    Topics: 8,11,14-Eicosatrienoic Acid; Cytosol; Epidermal Cells; Epidermis; Epoxide Hydrolases; Esterification; Humans; Hydroxyeicosatetraenoic Acids; Phosphatidylcholines; Phosphatidylethanolamines; Phospholipids; Psoriasis; Reference Values; Skin

2002
Occurrence of hepoxilins and trioxilins in psoriatic lesions.
    The Journal of investigative dermatology, 1998, Volume: 110, Issue:4

    We recently found that normal human epidermis produces relatively high amounts of hepoxilins and trioxilins in vitro. Therefore, the aim of this study was to demonstrate the presence of these compounds in psoriatic lesions. Extracts from scales of patients with chronic stable plaque psoriasis were analyzed by a combination of high performance liquid chromatography and gas chromatography-mass spectrometry techniques. We found that the levels of hepoxilin B3 were more than 16-fold higher in psoriatic scales than in normal epidermis (3.2+/-2.3 and < 0.2 ng per mg, respectively), whereas hepoxilin A3 was not detected in any sample. Trioxilins were semiquantitated and referred to 12-hydroxyeicosatetraenoic acid, ratios of trioxilins A3 and B3 12-hydroxyeicosatetraenoic acid in psoriatic lesions were 0.65+/-0.23 and 0.32+/-0.28, respectively, and they were not detected in normal epidermis. The presence of a great amount of trioxilin A3 strongly suggests that hepoxilin A3 was present in psoriatic lesions and it was totally degraded to trioxilin A3 during the analysis procedure. Our results demonstrate that hepoxilins and trioxilins are produced by human skin in vivo and that the levels of these compounds are increased in psoriasis. The reported biologic activities of hepoxilins indicate that they could amplify and maintain the inflammatory response. Our results reinforce the idea that these compounds could play a role as mediators in the inflammatory response in skin, particularly in psoriasis.

    Topics: 8,11,14-Eicosatrienoic Acid; Chromatography, High Pressure Liquid; Epidermis; Gas Chromatography-Mass Spectrometry; Humans; Hydroxyeicosatetraenoic Acids; Psoriasis; Reference Values

1998
Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures.
    Acta dermato-venereologica, 1996, Volume: 76, Issue:6

    Leukotriene A4 hydrolase is a key enzyme in the biosynthesis of leukotriene B4, a potent pro-inflammatory compound. The purpose of this study was to determine the capacity of antiinflammatory and anti-proliferative compounds to regulate the levels and activity of leukotriene A4 hydrolase in cultured human keratinocytes. The content of leukotriene A4 hydrolase was determined by Western blot analysis, and the activity of leukotriene A4 hydrolase was expressed as the leukotriene B4 formation after incubation of keratinocyte cultures with leukotriene A4. Leukotriene B4 was measured by revered-phase high performance liquid chromatography. Preincubation for 10 min of the cultured keratinocytes with the leukotriene A4 hydrolase inhibitor RP 64699 (0.1-10 microM) caused a significant dose-dependent inhibition of leukotriene B4 formation (IC50 = 0.7 microM). Cyclosporin A (0.1 micrograms/ml and 1.0 micrograms/ml) had no direct effect on leukotriene A4 hydrolase activity, but after incubation for 72 h there was a decrease in the mean leukotriene B4 formation per culture dish (35% and 48%, respectively). The decreased leukotriene B4 formation was caused mainly by a decrease in the mean leukotriene A4 hydrolase content per mg protein (30.1% at 0.1 micrograms/ml cyclosporin A and 40.0% at 1.0 micrograms/ml cyclosporin A), although keratinocyte proliferation was also slightly decreased. Incubations with 1.25-dihydroxyvitamin D3 (10(-7)-10(-10) M), all-trans retinoic acid (10(-6)-10(-10) M), eicosartienoic acid (10(-6)-10(-8) M), dexamethasone (10(-5)-10(-7) M), interferon-gamma (10 and 100 units/ml) or methotrexate (0.1-10 micrograms/ml) had no effect on either the leukotriene B4 formation or the amount of leukotriene A4 hydrolase in keratinocyte cultures. These results show that cyclosporin A, in contrast to other anti-inflammatory and anti-proliferative compounds, inhibits the level of leukotriene A4 hydrolase in keratinocyte cultures. Since similar cyclosporin A concentrations are obtained during treatment of psoriasis with cyclosporin A, the effect on leukotriene A4 hydrolase may play a role in the anti-inflammatory action of cyclosporin A.

    Topics: 8,11,14-Eicosatrienoic Acid; Anti-Inflammatory Agents; Antineoplastic Agents; Calcitriol; Cells, Cultured; Cyclosporine; Dexamethasone; Down-Regulation; Epoxide Hydrolases; Humans; Interferon-gamma; Keratinocytes; Leukotriene B4; Methotrexate; Psoriasis; Thiophenes; Tretinoin

1996
Incorporation of 15-hydroxyeicosatrienoic acid in specific phospholipids of cultured human keratinocytes and psoriatic plaques.
    Experimental dermatology, 1995, Volume: 4, Issue:2

    15-hydroxyeicosatrienoic acid, 15-HETrE, the 15-lipoxygenase product of dihomogammalinolenic acid (DGLA), can inhibit the biosynthesis of the proinflammatory eicosanoids leukotriene B4 (LTB4) and 12-hydroxyeicosatetraenoic acid (12-HETE). The purpose of the present study was to investigate the incorporation of [14C]15-HETrE in specific membrane phospholipids of cultured human keratinocytes in vitro. [14C]15-HETrE was rapidly incorporated into keratinocytes. When a plateau was reached after 3 hours, 15% of the added radioactivity was incorporated into lipids; 96.5% into phospholipids (PL) and 3.5% into neutral lipids (NL). Within the phospholipid classes, [14C]15-HETrE showed selectivity for incorporation into phosphatidylinositol (PI). The mean proportion of [14C]15-HETrE in the PI, phosphatidylcholine (PC) and phosphatidylethanolamine (PE) was 83.2%, 8.5% and 8.3%, respectively. We then investigated the incorporation of 15-HETrE in epidermal phospholipids of psoriatic skin intralesionally injected with 15-HETrE. Four patients took part in the study. In each patient four identical plaques were injected with 0.65 ml of 2.0 microM, 6.2 microM, 18.6 microM of 15-HETrE (0.4 micrograms, 1, 2 micrograms and 3.6 micrograms respectively) or 0.65 ml of 0.88% NaCl twice a week. After 3 wk keratome biopsies were obtained from the treated plaques. Phospholipids extracted from the skin biopsies were separated into major classes by two-dimensional thin layer chromatography. 15-HETrE was then released from specific phospholipids after treatment with phospholipase A2 and identified by reverse phase and straight phase high performance liquid chromatography. There was a dose-dependent incorporation of 15-HETrE into the specific phospholipids PI and PC. When expressed as ng 15-HETrE/micrograms phospholipid phosphate, 15-HETrE accumulated preferentially in PI.(ABSTRACT TRUNCATED AT 250 WORDS)

    Topics: 8,11,14-Eicosatrienoic Acid; Anti-Inflammatory Agents, Non-Steroidal; Cells, Cultured; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Humans; Hydroxyeicosatetraenoic Acids; Injections, Intralesional; Keratinocytes; Phosphatidylcholines; Phosphatidylinositols; Phospholipases A; Phospholipases A2; Phospholipids; Psoriasis

1995
Prostaglandin precursors in plasma phospholipids of patients with psoriasis: effects of treatment with coal tar.
    Prostaglandins, leukotrienes, and medicine, 1984, Volume: 14, Issue:2

    Plasma phospholipids of patients with psoriasis have significantly reduced levels of dihomogammalinolenic acid (20:3n-6), arachidonic acid (20:4n-6) and adrenic acid (22:4n-6), the precursors of the 1, 2 and homo-2 series of prostaglandins (PGs). Concentrations of the 3 series PG precursor, eicosapentaenoic acid (20:5n-3) were normal. Hospital treatment with a coal tar regime produced a rise in 20:3n-6 to levels which were significantly above normal.

    Topics: 8,11,14-Eicosatrienoic Acid; Adult; Coal Tar; Fatty Acids; Fatty Acids, Essential; Female; Humans; Linoleic Acid; Linoleic Acids; Male; Oleic Acid; Oleic Acids; Palmitic Acid; Palmitic Acids; Phospholipids; Prostaglandins; Psoriasis

1984